Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20220322010
TCTR20220322010
Not yet recruiting
Not Applicable

A cross-sectional study to determine the association between the dosage of colchicine and its pharmacokinetic profiles in real practice, and in gouty arthritis patients with varying degrees of renal impairment

aresuan university0 sites300 target enrollmentMarch 22, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionswhat is the correct dosage of colchicine in gouty patient who had renal impairment and received medication of dyslipidemia combination in prophylaxis goty flare?colchicine, gout, renal impairment, dosage, pharmacokinetic

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
what is the correct dosage of colchicine in gouty patient who had renal impairment and received medication of dyslipidemia combination in prophylaxis goty flare?
Sponsor
aresuan university
Enrollment
300
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 22, 2022
End Date
May 2, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
aresuan university

Eligibility Criteria

Inclusion Criteria

  • •1\.both sex age\>20
  • •2\.eGFR change not more than 25% by Cockcroft\-Gault Equation at least 1 month from inform consent
  • •3\. diagnosis in primary gout and receive colchicine for goty flare prophylaxis at least 3 month
  • •4\. if patients receive dyslipidemia medication (example in atorvastatin , simvastatin) , these medications must stable dosage at least 3 month
  • •5\. if patients who received incorrect dosage of colchicine were included in the study and finish in the protocol , the patients were adjusted correctly dosage of colchicine that was adjusted by eGFR. These patients can be included in the trail again, if they finish last protocol at least 4 months after last adjusted correctly dosage of colchicine.

Exclusion Criteria

  • •1\. colchicine or component of colchicine allergy
  • •2\. the cabnormal of AST, ALT imore than 2 time from normal limit in last atleast 3 months
  • •3\. received medication including Strong or moderate cytochrome P450 3A4 inhibitors
  • •\- Cobicistat
  • •\- Itraconazole
  • •\- Ketoconazole
  • •\- Voriconazole
  • •\- Clarithromycin
  • •\- Ciprofloxacin
  • •\- Erythromycin

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
nderstanding association between Prakriti and Self Esteem.
CTRI/2022/07/043778ational Institute of Ayurveda Jaipur500
Not yet recruiting
Not Applicable
To find relation between sleep and physical fitness in healthy individuals
CTRI/2024/03/063680Ch.Brahma Prakash Ayurved Charak Sansthan
Completed
Not Applicable
Cross-sectional Observational Study on Association between Suitability of CPAP Mask and Morphology of Face in Japanese Patients with Sleep Apnea SyndromeSleep Apnea Syndrome
JPRN-UMIN000022643The Center for Sleep Disordered Breathing, Komagamine Clinic50
Not yet recruiting
Not Applicable
Clinical study to understand the relation between ayurveda parameters and modern parameters of assessing the body tissues.
CTRI/2024/07/071066Sunad Gardan
Completed
Not Applicable
A cross-sectional study assessing the risk of sacrcopenia for nonalcoholic fatty liver disease and comparing the effect of sacropenia for fatty liver according to relative muscles adjustment method.
KCT0004474Hanyang University Seoul Hospital964